^
    CANCER:

    Genito-urinary Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    PD1 inhibitor
    nivolumab
    pembrolizumab
    toripalimab-tpzi
    cemiplimab-rwlc
    		0
    PD1 inhibitor
    camrelizumab
    tislelizumab
    PF-06801591
    sintilimab
    retifanlimab-dlwr
    zimberelimab
    dostarlimab-gxly
    PARP inhibitor
    olaparib
    		1
    PARP inhibitor
    rucaparib
    niraparib
    talazoparib
    IMP4297
    Krabeva (bevacizumab biosimilar)
    bevacizumab-tnjn
    bevacizumab-adcd
    		2
    VEGF-A inhibitor
    bevacizumab
    bevacizumab-awwb
    bevacizumab-bvzr
    bevacizumab-maly
    Aybintio (bevacizumab biosimilar)
    PD-L1 inhibitor
    		3
    PD-L1 inhibitor
    atezolizumab
    durvalumab
    avelumab
    cisplatin
    cisplatin + gemcitabine
    		4
    DNA synthesis inhibitor
    gemcitabine
    mitomycin urothelial gel
    gemcitabine-releasing intravesical system
    leuprolide 6-month depot
    leuprolide acetate
    		5
    GnRH agonist
    triptorelin
    histrelin acetate
    goserelin acetate
    leuprorelin depot
    mTOR inhibitor
    		6
    mTOR inhibitor
    everolimus
    temsirolimus
    Androgen receptor inhibitor
    enzalutamide capsule
    		7
    Androgen receptor inhibitor
    darolutamide
    bicalutamide
    enzalutamide capsule + EPI-7170
    SID 3712502
    pazopanib
    cabozantinib tablet
    		8
    Multi-tyrosine kinase inhibitor
    cabozantinib capsule
    midostaurin
    anlotinib
    ponatinib
    FGFR inhibitor
    BAY 1163877
    infigratinib
    ABSK091
    		9
    FGFR inhibitor
    pemigatinib
    futibatinib
    ARQ 087
    Debio 1347
    AZ8010
    abiraterone acetate + histrelin acetate
    		10
    CYP17A1 inhibitor, GnRH agonist
    abiraterone acetate + goserelin acetate
    abiraterone acetate + triptorelin
    abiraterone acetate + leuprolide acetate
    triptorelin + nilutamide
    leuprolide acetate + nilutamide
    		11
    Androgen receptor antagonist, GnRH agonist
    histrelin acetate + nilutamide
    goserelin acetate + nilutamide
    leuprolide acetate + apalutamide
    12
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    CYP17A1 inhibitor
    		13
    CYP17A1 inhibitor
    abiraterone acetate
    abiraterone acetate
    abiraterone acetate
    cetuximab
    		14
    EGFR inhibitor
    erlotinib
    icotinib
    15
    IFNα stimulant, VEGF-A inhibitor
    bevacizumab + pegylated interferon α -2a
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    5-fluorouracil
    		16
    Thymidylate synthase inhibitor
    capecitabine
    5-fluorouracil
    17
    GnRH antagonist
    degarelix
    relugolix
    etoposide IV
    		18
    Topoisomerase II inhibitor
    mitoxantrone
    doxorubicin hydrochloride
    pembrolizumab + axitinib
    		19
    VEGFR inhibitor, PD1 inhibitor
    toripalimab-tpzi + axitinib
    sintilimab + axitinib
    20
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    21
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    apalutamide
    		22
    Androgen receptor antagonist
    EPI-7386
    BMS-641988
    23
    c-MET inhibitor
    c-MET inhibitor
    savolitinib
    24
    Microtubule inhibitor
    cabazitaxel
    25
    Tubulin polymerization promoter
    carboplatin
    26
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    27
    HIF-2α inhibitor
    belzutifan
    28
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    29
    VEGFR inhibitor
    VEGFR inhibitor
    axitinib
    30
    IFNα stimulant
    nadofaragene firadenovec-vncg
    31
    Bifunctional alkylating agent
    ifosfamide
    32
    Topoisomerase II inhibitor, RNA synthesis inhibitor
    dactinomycin
    33
    VEGF-A inhibitor, mTOR inhibitor
    bevacizumab + everolimus
    34
    Tubulin polymerization promoter, Microtubule inhibitor
    carboplatin + cabazitaxel
    35
    Topoisomerase II inhibitor, DNA inhibitor, DNA synthesis inhibitor
    cisplatin + etoposide oral
    36
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    37
    Immunostimulant, Prostatic acid phosphatase inhibitor
    sipuleucel-T
    38
    Bone resorption factor inhibitor, Osteoclast inhibitor
    zoledronic acid
    39
    Tubulin polymerization promoter, Bcl2 inhibitor
    carboplatin + paclitaxel
    paclitaxel
    40
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    cisplatin + irinotecan
    41
    Ionizing radiation emitter, PSMA inhibitor
    PNT2002
    lutetium Lu 177 vipivotide tetraxetan
    42
    Androgen receptor degrader
    ARV-110
    AC0176
    43
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    44
    PI3K inhibitor, AKT inhibitor
    RG7440
    45
    FGFR inhibitor, PD-L1 inhibitor
    atezolizumab + BAY 1163877
    durvalumab + ABSK091
    46
    PD1 inhibitor, PI3Kγ inhibitor
    nivolumab + IPI-549
    47
    CTLA4 inhibitor
    CTLA4 inhibitor
    ipilimumab
    48
    Androgen receptor inhibitor, PARP inhibitor
    talazoparib + enzalutamide capsule
    49
    ALK inhibitor
    crizotinib
    alectinib
    50
    AXL inhibitor, GAS6 inhibitor
    AVB-500
    51
    PLK1 inhibitor
    PCM-075
    52
    HLA G-targeted CAR-T immunotherapy
    IVS-3001
    53
    Apoptosis stimulant
    Alpha1H
    54
    IL-15 superagonist
    nogapendekin alfa inbakicept-pmln
    55
    Immunostimulant
    RV001
    56
    CD70-targeted CAR-T immunotherapy
    ALLO-316
    57
    CLDN6-targeted CAR-T immunotherapy
    BNT211
    58
    Reactive oxygen species stimulant
    AU-011
    59
    PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab + cabozantinib tablet
    60
    PD1 inhibitor, PARP inhibitor
    nivolumab + rucaparib
    pembrolizumab + olaparib
    FGFR3 inhibitor
    		61
    FGFR3 inhibitor
    B-701
    TYRA-300
    MEK inhibitor
    		62
    MEK inhibitor
    trametinib
    PD-0325901
    63
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    64
    PARP inhibitor, AKT inhibitor
    olaparib + capivasertib
    65
    Androgen receptor inhibitor, mTOR inhibitor, DNA PK inhibitor
    enzalutamide capsule + CC-115
    66
    PD-L1 inhibitor, PARP inhibitor
    avelumab + talazoparib
    67
    HER2 inhibitor
    trastuzumab-pkrb
    trastuzumab
    68
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    pembrolizumab + INCB024360
    69
    HDAC inhibitor
    vorinostat
    70
    DNA PK inhibitor
    NU7441
    M3814
    71
    CYP11A1 inhibitor
    ODM-208
    72
    CDC7 kinase inhibitor
    LY3143921
    73
    VEGFR inhibitor, PARP inhibitor
    olaparib + cediranib
    74
    VEGF-A inhibitor, PI3Kγ inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    bevacizumab + albumin-bound paclitaxel + IPI-549
    75
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    abemaciclib
    76
    VEGFR-2 inhibitor
    ramucirumab
    77
    VEGFR inhibitor, mTOR inhibitor
    temsirolimus + axitinib
    78
    HIF-2α antagonist
    MK-3795
    79
    Microtubule inhibitor, CLDN6-targeted antibody-drug conjugate
    TORL-1-23
    IMAB027-vcMMAE
    80
    HDAC inhibitor, Multi-tyrosine kinase inhibitor
    pazopanib + CG-781
    81
    PD1 inhibitor, EphB4 inhibitor
    pembrolizumab + sEphB4-HSA
    82
    PD-L1 inhibitor, c-MET inhibitor
    durvalumab + savolitinib
    83
    PD1 inhibitor, ICOS agonist
    pembrolizumab + GSK3359609
    84
    PI3K inhibitor
    AN2025
    MEN1611
    85
    PI3Kβ inhibitor, PD1 inhibitor
    pembrolizumab + GSK2636771
    86
    PI3Kβ inhibitor
    GSK2636771
    87
    IL-6R antagonist, PD-L1 inhibitor
    atezolizumab + tocilizumab
    88
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    89
    Tubulin inhibitor
    vinblastine
    90
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    91
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    92
    PRMT5 inhibitor
    AMG 193
    EP
    FOLFOX
    GC
    ddMVAC
    GemPOx
    VAC
    		93
    Chemotherapy
    TIP
    VeIP
    VIP
    BEP
    GemOx
    VC
    CaT
    TI-CE
    94
    GnRH stimulant
    GnRH stimulant
    95
    Immunotherapy
    Immunotherapy
    96
    FGFR2 inhibitor
    FGFR2 inhibitor
    97
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    PD173074
    98
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    99
    VEGF inhibitor
    VEGF inhibitor
    100
    VEGFR inhibitor, Immunotherapy
    Immunotherapy + VEGFR inhibitor
    101
    ATM kinase inhibitor
    ATM kinase inhibitor
    102
    Glutamate inhibitor
    Glutamate inhibitor
    103
    Src kinase inhibitor, PARP inhibitor
    PARP inhibitor + Src kinase inhibitor
    104
    mTORC1 inhibitor
    mTORC1 inhibitor
    105
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    106
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    erdafitinib + Debio 1347
    docetaxel
    		107
    Microtubule stabilizer, Tubulin polymerization promoter
    carboplatin + docetaxel
    docetaxel
    108
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    109
    Nectin-4-targeted antibody-drug conjugate, Microtubule inhibitor
    enfortumab vedotin-ejfv
    110
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    111
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    112
    Tubulin polymerization promoter, PARP inhibitor
    PARP inhibitor + carboplatin
    113
    Nectin-4-targeted antibody-drug conjugate, PD1 inhibitor, Microtubule inhibitor
    pembrolizumab + enfortumab vedotin-ejfv
    114
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    115
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA inhibitor
    carboplatin + etoposide oral
    116
    Bifunctional alkylating agent, Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel + ifosfamide
    117
    VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
    tivozanib
    goserelin acetate + flutamide
    bicalutamide + goserelin acetate
    bicalutamide + triptorelin
    		118
    Androgen receptor inhibitor, GnRH agonist
    triptorelin + flutamide
    leuprolide acetate + bicalutamide
    leuprolide acetate + flutamide
    bicalutamide + histrelin acetate
    histrelin acetate + flutamide
    119
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel
    gemcitabine + paclitaxel
    120
    GnRH antagonist, CYP17A1 inhibitor
    abiraterone acetate + degarelix
    121
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + 5-fluorouracil
    5-fluorouracil + mitomycin
    122
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
    gemcitabine + ifosfamide + pegylated liposomal doxorubicin
    123
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + etoposide IV
    124
    CD122 agonist, IL-2 stimulant
    aldesleukin
    125
    TLR7 agonist, TLR8 agonist
    imiquimod
    126
    Tubulin polymerization promoter, DNA synthesis inhibitor, DNA cross linking agent, Bcl2 inhibitor
    gemcitabine + paclitaxel + oxaliplatin
    127
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    everolimus + lenvatinib
    128
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    129
    PD-L1 inhibitor, Androgen receptor inhibitor
    atezolizumab + enzalutamide capsule
    130
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    131
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    SHR-A1811
    132
    Nectin-4-targeted peptide-drug conjugate, Microtubule inhibitor
    BT8009
    133
    PSMA-targeted antibody-drug conjugate, Tubulin inhibitor
    JNJ-8177
    134
    Cell death stimulant, GM-CSF agonist
    CG0070
    135
    PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
    atezolizumab + cabozantinib tablet
    136
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, PD1 inhibitor, FGFR4 inhibitor
    erdafitinib + JNJ-63723283
    137
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    disitamab vedotin
    ado-trastuzumab emtansine
    138
    PIK3CA inhibitor, PARP inhibitor, PI3Kδ inhibitor
    rucaparib + copanlisib
    139
    Androgen receptor degrader, Androgen receptor inhibitor
    ONCT-534
    140
    PD1 inhibitor, Androgen receptor inhibitor
    pembrolizumab + enzalutamide capsule
    141
    PARP2 inhibitor, PARP1 inhibitor, CYP17A1 inhibitor
    abiraterone / niraparib
    142
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    toripalimab-tpzi + disitamab vedotin
    tislelizumab + disitamab vedotin
    143
    IGF-2 inhibitor, Androgen receptor inhibitor, IGF1 inhibitor
    enzalutamide capsule + BI-836845
    144
    PD-L1 inhibitor, PD1 inhibitor
    durvalumab + MEDI0680
    145
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor, FLT3 inhibitor
    ABT-869
    146
    PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
    bevacizumab + atezolizumab + IPI-549
    147
    TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-014
    148
    PD-L1 inhibitor, mTOR inhibitor, mTORC2 inhibitor
    durvalumab + AZD2014
    149
    CYP17A1 inhibitor, Androgen receptor inhibitor, Androgen receptor antagonist
    enzalutamide capsule + abiraterone acetate + apalutamide
    150
    PD-L1 inhibitor, CD47 inhibitor
    atezolizumab + GS-4721
    151
    CD137 agonist, HER2 inhibitor
    PRS-343
    152
    PD1 inhibitor, GDF15 inhibitor
    nivolumab + CTL-002
    153
    STAT3 inhibitor, PD1 inhibitor
    pembrolizumab + BBI608
    154
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA inhibitor, DNA synthesis inhibitor
    cisplatin + ifosfamide + etoposide oral
    155
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    156
    STEAP1-targeted antibody-drug conjugate, Microtubule inhibitor
    RG7450
    157
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    158
    Alkylating agent
    cyclophosphamide
    STAR-001
    159
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    etoposide IV + bleomycin
    160
    Ionizing radiation emitter, Androgen receptor inhibitor, PSMA inhibitor
    enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
    161
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    nivolumab + fam-trastuzumab deruxtecan-nxki
    162
    PD-L1 inhibitor, PI3K inhibitor, AKT inhibitor
    atezolizumab + RG7440
    163
    B7-H3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DS-7300
    164
    Ionizing radiation emitter, PD1 inhibitor, PSMA inhibitor
    pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
    165
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    166
    GnRH antagonist, CYP17A1 inhibitor, Androgen receptor antagonist
    abiraterone acetate + degarelix + bicalutamide implant
    167
    AXL inhibitor, Multi-tyrosine kinase inhibitor, GAS6 inhibitor
    cabozantinib tablet + AVB-500
    168
    Topoisomerase II inhibitor, Microtubule stabilizer, Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel + docetaxel + etoposide IV
    169
    VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sunitinib + pazopanib
    170
    Glutathione peroxidase 4 inhibitor, Ferroptosis inducer
    ML210
    171
    RAC1 inhibitor
    NSC23766
    172
    C4.4a-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY1129980
    173
    MAT2A inhibitor
    IDE397
    174
    EZH1 inhibitor, EZH2 inhibitor
    CPI-0209
    175
    Ferroptosis inducer
    erastin
    RSL3
    176
    Bcr-abl tyrosine kinase inhibitor
    INNO-406
    MK-2206
    		177
    AKT inhibitor
    capivasertib
    GSK690693
    178
    p53 reactivator
    APR-246
    APR-548
    179
    WEE1 inhibitor
    AZD1775
    180
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    181
    FGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + infigratinib
    182
    DDX5 degrader
    FL118
    183
    DNA methylation inhibitor
    TdCyd
    184
    DNA synthesis inhibitor, Cytidine deaminase inhibitor, DNA methylation inhibitor
    gemcitabine + EPI01
    185
    EZH2 inhibitor
    GSK2816126
    186
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    187
    pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + 4-methylumbelliferone
    188
    Androgen receptor antagonist, TMPRSS2 inhibitor
    GT0918
    189
    WDR5 inhibitor
    OICR-9429
    190
    AKT2 inhibitor, AKT1 inhibitor
    BAY 1125976
    191
    Androgen receptor inhibitor, AKT inhibitor
    enzalutamide capsule + capivasertib
    192
    ZG16B inhibitor
    PBP1510
    193
    PIK3CA inhibitor, Androgen receptor inhibitor, PI3Kδ inhibitor
    copanlisib + darolutamide
    194
    FGFR inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + Debio 1347
    195
    PRC2 inhibitor
    MRTX2219
    196
    TGM2 inhibitor
    MD102
    197
    BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
    OTX015
    198
    B7-H3-targeted antibody-drug conjugate, DNA replication inhibitor
    MGC018
    199
    ATR inhibitor
    M6620
    200
    ROR1 inhibitor
    UC-961
    201
    BTK inhibitor
    ibrutinib
    202
    UCHL1 inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + 6RK73
    203
    MAPK inhibitor, p38 inhibitor
    SB202190
    204
    CDK7 inhibitor
    SY‑079
    YPN-005
    205
    Integrin beta-6 -targeted antibody-drug conjugate, Microtubule inhibitor
    SGN-B6A
    206
    Androgen receptor inhibitor, Microtubule inhibitor, PSMA-targeted antibody-drug conjugate
    enzalutamide capsule + PSMA ADC
    207
    FGFR3-targeted antibody-drug conjugate, Microtubule inhibitor
    LY3076226
    208
    SLC44A4-targeted antibody-drug conjugate, Microtubule inhibitor
    ASG 5ME
    209
    DOT1L inhibitor
    EPZ004777
    EPZ-5676
    210
    KRAS G12C inhibitor
    sotorasib
    211
    Bcr-abl tyrosine kinase inhibitor, mTOR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + AZD8055
    212
    PD-L1 inhibitor, NK cell stimulant
    avelumab + CYNK-101
    213
    Adenosine A2A receptor antagonist
    AZD4635
    214
    MEK1 inhibitor
    cobimetinib
    215
    Adenosine A2A receptor antagonist, Androgen receptor antagonist
    apalutamide + AZD4635
    216
    FGFR4 inhibitor
    BLU 9931
    217
    EGFR inhibitor, IFN stimulant, TROP-2 inhibitor
    ABN202
    218
    FGFR3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AMB302
    219
    KRAS G12C inhibitor, mTORC1 inhibitor
    adagrasib + nanoparticle albumin-bound rapamycin
    sotorasib + nanoparticle albumin-bound rapamycin
    220
    Androgen receptor inhibitor, ERK inhibitor, AKT inhibitor
    darolutamide + ONC201
    221
    NF-κB inhibitor, SYK inhibitor
    BAY-61-3606
    222
    CD3 agonist, STEAP1 inhibitor
    AMG 509
    223
    Ionizing radiation emitter, CD37 inhibitor
    177Lu-satetraxetan-lilotomab
    224
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    225
    PSMA-targeted CAR-T immunotherapy
    AUTO7
    226
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    227
    CYP17A1 inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + abiraterone acetate
    228
    CD3 agonist, PSMA inhibitor
    JNJ-63898081
    229
    HER3 inhibitor, α radiation emission
    Ac-225 ErbB3 targeted radiotherapy
    230
    CA6-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR566658
    231
    DNA replication inhibitor, PSMA-targeted antibody-drug conjugate
    MEDI3726
    ADCT-212
    232
    Microtubule stabilizer, Tubulin polymerization promoter, Microtubule inhibitor
    docetaxel + cabazitaxel
    233
    GnRH stimulant, CYP17A1 inhibitor, Androgen receptor antagonist
    abiraterone acetate + bicalutamide implant + leuprorelin depot
    234
    CEACAM5-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    IMMU-130
    235
    CYP17A1 inhibitor, PI3K inhibitor, AKT inhibitor
    abiraterone acetate + RG7440
    236
    MCL1 inhibitor
    PRT1419
    237
    AXL-targeted antibody-drug conjugate, Microtubule inhibitor
    BA3011
    238
    Aurora kinase A inhibitor
    MLN8237
    239
    CDH6-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    CUSP06
    240
    pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sorafenib + sunitinib
    241
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    242
    Ionizing radiation emitter
    radium Ra-223 dichloride
    243
    AR-V7 degrader
    HSK38008
    244
    Androgen receptor inhibitor, AR-V7 degrader
    enzalutamide capsule + HSK38008
    245
    PIK3C3 inhibitor, FGFR inhibitor
    MPT0L145
    No biomarker
    PD-L1 expression
    PD-L1 overexpression
    TMB-H + PD-L1 expression
    DDR + PD-L1 expression
    PD-L1 underexpression
    PD-L1 expression + T-cell gene signature
    PD-L1 elevation
    PD-L1 negative
    FGFR3 mutation
    FGFR3 fusion
    FGFR3 R248C
    FGFR3 Y373C
    FGFR3 G370C
    FGFR3 S249C
    FGFR3 expression
    FGFR3 rearrangement
    FGFR3 Y375C
    FGFR3 overexpression
    FGFR3 G380R
    FGFR3 A393E
    FGFR3 L496V
    FGFR3 S247C
    FGFR3 K508M
    FGFR3 V443M
    FGFR3 V443L
    MET amplification
    MET mutation
    MET fusion
    MET expression
    MSI-H/dMMR
    PTEN deletion
    PTEN mutation
    PTEN negative
    MSI-L/dMMR
    PTEN expression
    PTEN N323fs*21
    PTEN overexpression
    PTEN underexpression
    AR wild-type
    AR splice variant 7 negative
    AR mutation
    AR T878A
    AR elevation
    AR H875Y
    AR T878S + AR H875Y
    AR T878A + AR H875Y
    AR T878S
    AR overexpression
    AR positive
    AR F876L
    AR splice variant 7
    AR splice variant 7 expression
    AR F877L
    AR amplification
    AR T877A
    AR L329W
    AR W741L
    AR expression
    AR H100Q
    AR W741C
    AR L702H
    AR D891H
    AR F877L + AR T878A
    AR splice variant 9
    TMB-H
    FGFR mutation
    BRCA2 mutation
    BRCA2 deletion
    BRCA2 positive
    BRCA2 biallelic inactivation
    FGFR fusion
    FGFR overexpression
    TMB-H + DDR
    BRCA2 L557*
    FGFR expression
    BRCA2 A902fs*2
    BRCA2 underexpression
    BRCA2 amplification
    BRCA2 exon 11 deletion
    HER-2 positive
    BRCA1 mutation
    BRCA1 positive
    HER-2 mutation
    HER-2 overexpression
    HER-2 expression
    BRCA1 underexpression
    BRCA1 deletion
    BRCA1 N1018fs*8
    HER-2 amplification
    BRCA1 biallelic inactivation
    BRCA1 expression
    FANCL mutation
    ERCC2 E606Q
    ERCC2 D609E
    ERCC2 D609G
    ERCC2 G665A
    ERCC2 mutation
    ERCC2 N238S
    ERCC2 E606G
    ERCC2 P463L
    ERCC2 V242F
    ERCC2 Y24C
    MTOR mutation
    MTOR E2014K
    MTOR E2419K
    MTOR Q2223K
    MTOR overexpression
    FOLH1 expression
    PBRM1 mutation
    ATM positive
    ATM mutation
    ATM deletion
    PBRM1 deletion
    HRAS mutation
    HRAS G13R
    HRAS G12C
    HRAS Q61R
    HRAS H27_28fs*
    HRAS G12S
    FOLH1 overexpression
    FOLH1 positive
    PBRM1 overexpression
    PBRM1 negative
    HRAS Q61
    PBRM1 underexpression
    ATM biallelic inactivation
    ATM underexpression
    KDR rs2071559
    FGFR2 fusion
    FGFR2 mutation
    KDR C482R
    KDR expression
    FGFR2 A391E
    FGFR2 underexpression
    KDR overexpression
    RNASET2 overexpression
    CD8 expression
    FLT1 rs9554320
    FGFR3-TACC3 fusion
    TSC1 deletion
    FGFR1 overexpression
    TSC1 mutation
    FGFR1 mutation
    ERBB3 G284R
    ERBB3 V104M
    ERBB3 R103G
    ERBB3 mutation
    FGFR1 expression
    FGFR3-TACC3 F17T8
    FGFR1 amplification
    CD8 overexpression
    TSC1 deletion
    FLT1 expression
    TSC1 1907_1908del
    ERBB3 expression
    FLT1 overexpression
    FGFR3-TACC3 fusion + FGFR3 V555M
    HRD
    AXL-L
    ARID1A mutation
    HLA-G positive
    ROBO3 mutation
    PD-1 expression
    MSH2 deletion
    MSH2 mutation
    BAP1 mutation
    BAP1 negative
    BAP1 I696T
    PD-1 overexpression
    BAP1 deletion
    AXL expression
    AXL overexpression
    PD-1 elevation
    MTAP deletion
    VHL mutation
    SPOP mutation
    ALK rearrangement
    RB1 mutation
    HDAC2 expression
    FANCA deletion
    BRCA2 mutation + ATM mutation
    CTLA4 underexpression
    CDK12 mutation
    FH mutation
    PALB2 mutation
    TSC2 mutation
    FANCA mutation
    TFE3 translocation
    MLH1 mutation
    CYP17A1 expression
    EGFR amplification
    VCP-TFE3 fusion
    TMB-H + PD-L1 negative
    MSH6 mutation
    PIK3CA mutation
    PD-L1 expression + TMB-H
    MSH2 mutation + MSH6 mutation
    MSH2 negative + MSH6 negative
    CYP17A1 V366M
    PALB2 deletion
    HMOX1-L
    MSH6 deletion
    HGF-L
    HGF expression
    EGFR L858R
    TSC2 H1620R + TSC2 Y1650C
    PIK3CA M1043I
    MLH1 deletion
    CTLA4 promoter hypomethylation
    BRCA2 deletion + ATM mutation
    CXCL10 expression
    HMOX1 expression
    WRN mutation
    FH deletion
    WRN expression
    CXCL10 overexpression
    HDAC2 mutation
    CDK12 deletion
    RB1 expression
    VHL promoter methylation
    ERBB3 mutation + TMB-H
    HGF elevation
    CXCL10 elevation
    RB deletion
    PIK3CA mutation + MSI-L/dMMR
    PIK3CA amplification
    MTAP mutation
    FH negative
    RB1 deletion
    VHL deletion
    KHDRBS1 overexpression
    GNG4 overexpression
    LRP1B mutation
    CXCR3 overexpression
    STEAP1 expression
    BRCA1 mutation + ATM mutation
    CPM elevation
    Apolipoprotein B elevation
    ITGAX underexpression
    APH1A overexpression
    NOTCH3 underexpression
    PECAM1 underexpression
    VTCN1 overexpression
    TUBB1 rs151352
    CYP2C8 rs1341164
    TP53 mutation
    SAAL1 overexpression
    YBX1 rs10493112
    DRD
    EFNB2 expression
    CD163 overexpression
    CD68 overexpression
    B2M overexpression
    TNFRSF9 positive + CD4 positive
    KDM6A mutation
    CD3G overexpression
    NCAM1 overexpression
    TNFRSF9 positive + CD8 positive
    CD4 underexpression
    LAG3 positive + CD4 positive
    CEACAM1 overexpression
    PD-L1 expression + CD14 positive
    PD-L2 overexpression
    ATR mutation
    BLM mutation
    PMS1 expression
    MLL2 mutation
    FANCE expression
    POLR2L expression
    CD19 overexpression
    PAX5 overexpression
    PD-L1 overexpression + APOBEC3B overexpression
    ELTD1 expression
    NT5E underexpression
    TNFRSF9 elevation
    TMB-H + MLL2 mutation
    TMB-H + KDM6A mutation
    TMB-H + TERT promoter mutation
    TMB-H + PIK3CA mutation
    ISLR overexpression
    FGFR2-CASP7 fusion
    AXL elevation + GAS6 elevation
    RAD50 mutation
    FANCG mutation
    FGFR2-BICC1 fusion
    FANCI mutation
    NECTIN4 expression
    FANCM mutation
    TGFB1 underexpression
    TUBB3 overexpression
    FGF10 amplification
    PTTG1 overexpression
    KDM5D overexpression
    KIFC1 expression
    PARP1 underexpression + PBRM1 mutation
    CDKN2A mutation
    FGF mutation
    LAMP3 expression
    CXCL10 overexpression + LAMP3 overexpression
    EPHB2 expression
    LDH elevation
    PSMA1 overexpression
    FGFR mutation + PD-L1 expression
    CLDN6 expression
    CD276 overexpression
    CA9 expression
    TP53 mutation + MDM2 mutation
    SLC35A2 overexpression
    CD31 expression
    GBP5 expression
    IFNG expression
    CXCL9 expression
    ITIH5 overexpression
    PYCR1 underexpression
    IGF1 overexpression
    SRRM4 overexpression
    TMEM72 underexpression
    NPHS1 underexpression
    NANOGNB mutation
    TNFRSF18-H
    SYNE1 mutation
    IL18BP expression
    CCDC69 overexpression
    TLR3 overexpression
    VEGFA expression
    CSF1 expression
    SNAI2 deletion
    TIMP1 expression
    WDR72 overexpression + PBRM1 mutation
    WDR72 overexpression
    BRCA2 mutation + SPOP mutation
    TERT promoter mutation
    BRAF mutation
    ANGPT2 expression
    TMB-H + PD-L1 expression + MSI-L/dMMR
    IL18 expression
    PBRM1 mutation + SETD2 mutation
    MSI-H + MSH2 expression + MSH6 expression
    ARID2 H1495fs*8
    SMARCB1 deletion
    RB1 mutation + PD-L1 expression
    IL6-L
    CXCL8-L
    TLR4-L
    SPP1-L
    NRF1-BRAF fusion
    GNAQ mutation
    IKZF2-L
    HAVCR2 expression
    MSH4 L359I
    KDM5C mutation
    KMT2C mutation
    ERVE-4 expression
    PDGFRA expression
    RNF43 mutation
    AFP elevation
    MSI-H/dMMR + TMB-H
    miR-138 underexpression + miR-497 overexpression
    RB1 mutation + TP53 mutation
    EWSR1-POU5F1 fusion
    PMS2 mutation + MLH1 mutation
    MSH2 mutation + MSH6 mutation + BRCA1 mutation
    NF2 mutation
    BIRC5 expression
    FGFR3-BAIAP2L1 fusion
    AKT1 mutation + AR mutation
    SETD2 mutation + TP53 mutation
    PMS2 mutation
    SND1-BRAF fusion
    CHEK2 mutation
    TMB-H + RB1 mutation + PD-L1 underexpression
    TET1 mutation
    FANCF mutation
    FLCN mutation
    KIM1 expression
    BRIP1 mutation
    CXCL13 expression
    ATRX mutation
    PCSK9 underexpression
    SPOP mutation + CHD1 deletion
    CXCL13 mutation + ARID1A mutation
    TFEB translocation
    HIF1A expression
    CYB5A rs1790834
    IFNA1 expression
    BRCA1 mutation + TP53 mutation
    BRCA2 mutation + TP53 mutation
    BARD1 mutation
    IL6ST elevation
    RAD54L mutation
    RAD51D mutation
    IL6R L
    RAD51C mutation
    KRAS amplification
    RAD51B mutation
    CHEK1 mutation
    CD93 underexpression
    CREBBP mutation
    ERCC1 underexpression
    CALCR overexpression
    CXCL13 elevation
    CXCL8 elevation
    KIM1 elevation
    IL6 elevation
    VEGFA elevation
    KDM5D amplification
    KDM6A amplification
    CD276 expression
    TP53 expression
    PSMA1 expression
    TP53 deletion
    CDKN2A deletion
    TP53 R175H
    SETD2 mutation
    SETD2 deletion
    KRAS mutation
    TERT overexpression
    RAD51C expression
    NT5E overexpression
    NECTIN4 underexpression
    CYP2C8 rs1058932
    KRAS G12C
    BRAF V595E
    VEGFA overexpression
    APOBEC mutagenesis
    TSG gene expression signature
    High MHC-II signature
    Low MLR
    DDR
    Chr t(22)
    AR-V7 expression
    SBS5 signature
    BONSAI high signature
    Immune response prediction signature
    T-cell-inflamed GEP signature
    AR-V7 negative
    IFNG 4-genes signature
    IFNG gene signature
    IFNG gene signature overexpression
    12-CK gene signature
    AR-V7 mutation
    AP positive signature
    Low NLR
    MYC amplification
    HLA-A*03
    ETS rearrangment
    ERG overexpression
    ETV1 overexpression
    SLC44A4 expression
    RAC1 deletion
    miR-155 underexpression
    GAS5 underexpression
    ALCAM elevation
    CEACAM5 expression
    SPINK1 overexpression
    CA6 expression
    HMGA2 overexpression
    CD27 overexpression
    IL7 elevation
    GSDMB expression
    STK11 expression
    CDKN2B mutation
    ESRP1-RAF1 fusion
    SLC45A3-BRAF fusion
    IRF8 expression
    BTK overexpression
    FLT3 overexpression
    IL2R overexpression
    ARG1 overexpression
    ATM mutation + CDK12 mutation
    CFLAR expression
    SMARCA4 mutation
    NOTCH1 mutation + MSI-L/dMMR
    ELF3 mutation + MSI-L/dMMR
    COL6A1 overexpression
    SPI1 overexpression
    EPAS1 G323E
    ELF3 mutation + TMB-L + MSI-L/dMMR
    AR-V7 positive
    XPA expression
    ZEB1 expression
    SNAI1 expression
    ADAMTS1 expression
    KLK4 expression
    KLK2 expression
    FGF3 mutation
    CCNE1 amplification
    CTBP1 deletion
    ACRBP amplification
    GNAS amplification
    LRP10 deletion
    TMB-H + CDKN2B mutation
    TMB-L + RB1 mutation
    KRT20 overexpression
    H19 overexpression
    FGF4 mutation
    FGF19 mutation
    SULT1A3 amplification
    NOTCH1 mutation + TMB-L + MSI-L/dMMR
    BRCA2 mutation + CHEK2 mutation
    BRCA2 mutation + CDK12 mutation
    AKT1 mutation
    KDM4B overexpression
    NRAS G12D
    TMPRSS2-ERG fusion
    UGT1A9 expression
    KIT mutation
    ADCYAP1 deletion
    NOTCH1 deletion
    EPAS1 S304M
    BRCA1 mutation + BRCA2 mutation
    IL20RB overexpression
    EPAS1 overexpression
    CD44 positive
    EZH2 amplification
    DNMT3A amplification
    PREX2 amplification
    PIK3CB amplification
    SLC3A2 expression
    GPX4 expression
    CD44 expression
    SLC7A11 expression
    ACSM3 overexpression
    BRCA2 deletion + RB1 deletion
    ACSM1 overexpression
    SALL4 positive + POU5F1 positive + KIT positive + PLAA positive
    BBOX1 underexpression
    HER-2 mutation + TMB-H
    YTHDC1 underexpression
    TERC overexpression
    DKC1 overexpression
    LYPD3 expression
    ZRANB1 overexpression
    TUBA1C overexpression
    Chr del(9)(p21.3)
    TNFSF13B elevation
    IL13RA2 overexpression
    FGF4 amplification + HRAS Q61R + TP53 672+2T>G
    FSCN1 elevation
    AXL overexpression + PD-L1 expression
    NUSAP1 overexpression
    High NLR
    DDX39B overexpression
    FGF3 amplification + HRAS Q61R + TP53 672+2T>G
    CYP11B1 rs4736349
    FGF19 amplification + HRAS Q61R + TP53 672+2T>G
    PD-1-L + PD-L1 elevation
    CXCL11 elevation
    NEIL3 deletion
    PTGR1 elevation + HRD
    HYAL4 V1
    FGFR2 underexpression + FGFR3 overexpression
    BAX underexpression
    TET2 deletion + DNMT3A mutation
    FGFR2 underexpression + FGFR3 mutation
    miR-572 overexpression
    PAI1 elevation
    ITGB6 expression
    WDR5 overexpression
    CXCR4 overexpression
    TDO2 overexpression
    CXCL12 elevation
    ZG16B positive
    GPC1 overexpression
    PLK1 overexpression
    SNHG1 deletion
    CDH6 expression
    TGM2 overexpression
    AR-V7 overexpression
    CCL4 elevation
    OXCT1 expression
    ROR1 expression
    WNT5A overexpression + FZD2 overexpression
    PRCC-TFE3 fusion
    RAD52 underexpression
    HSD3B1 1245A>C
    MTA2 overexpression
    LAG3 expression
    PGF overexpression
    VEGFC underexpression
    PDGFA underexpression
    TSPYL1 P62S
    PHLPP1 deletion
    FLT4 overexpression
    ZFHX3 deletion
    VEGFD overexpression
    SPARC amplification
    PD-L1 expression + REV3L overexpression
    VEGFB overexpression
    PD-L1 expression + MTOR overexpression
    MCAM overexpression
    KAT6A-NRG1 fusion
    PTEN deletion + KRAS G12C
    CD70 expression
    HDAC5 deletion
    HAS3 expression
    ACTA2 underexpression
    FOXA mutation
    AR expression + CYP17A1 expression
    AKR1C3 expression
    CHD1 deletion
    PPP2R2A mutation
    SRF overexpression
    DAPK1 underexpression
    PLAC8 overexpression
    SOX2 expression
    MYCN amplification
    MAST4 mutation
    FGFR4 amplification
    TROP2 positive
    MTAP mutation + CDKN2A mutation
    Chr del(10)
    HLA-DQB1*03:01